Regdanvimab for patients with mild-to-moderate COVID-19: a retrospective cohort study and subgroup analysis of patients with the Delta variant
Young Rock Jang, Yoon Ju Oh, Jin Yong Kim
International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.12.035
Objectives: To evaluate the efficacy and safety of regdanvimab, a neutralizing antibody, in patients with mild-to-moderate SARS-CoV-2 including against the Delta variant. Methods: A single-center, retrospective, observational cohort study in adults with confirmed COVID-19. The primary end point was the proportion of patients deteriorating with peripheral oxygen saturation < 90% in room air, requiring supplemental oxygen therapy above high flow, or experiencing mortality due to COVID-19 up to day 28. Results: A total of 722 patients were eligible; 418 received regdanvimab and 304 received standard of care (SoC), of whom 71.1% (297/418, regdanvimab) and 37.8% (115/304, SoC) were infected with the Delta variant. The proportion of patients with a primary end point event was significantly lower with regdanvimab than SoC (3.1% vs 9.9%; difference: -6.8 [95% confidence interval: -10.9, -2.8]; P = 0.0 0 02). A similar trend was observed in the Delta variant subgroup (regdanvimab, 2.7% vs SoC, 7.0%; difference -4.3 [95% confidence interval: -10.8, 0.2]; P = 0.0827). The secondary efficacy end points supported the primary analysis findings in the overall cohort and Delta variant subgroup. No new safety signals were identified. Conclusion: Regdanvimab demonstrated clinical efficacy in the overall cohort and may provide a clinical benefit for patients with mild-to-moderate COVID-19 infected with the Delta variant.
Author contributions YRJ, YJO, and JYK were jointly responsible for the acquisition/interpretation of data, conception, and design of the study. Statistical analysis was conducted by Celltrion, Inc. All authors contributed to manuscript development and approved the final version.
Supplementary materials Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.ijid.2022.12.035 .
References
Baral, Yin, James, Treatment and prevention strategies for the COVID 19 pandemic: a review of immunotherapeutic approaches for neutralizing SARS-CoV-2, Int J Biol Macromol,
doi:10.1016/j.ijbiomac.2021.07.013Bierle, Ganesh, Razonable, Breakthrough COVID-19 and casirivimabimdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge, J Clin Virol,
doi:10.1016/j.jcv.2021.105026Dougan, Nirula, Azizad, Mocherla, Gottlieb et al., Bamlanivimab plus etesevimab in mild or moderate Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2102685Gupta, Gonzalez-Rojas, Juarez, Casal, Moya et al., Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab, N Engl J Med,
doi:10.1056/NEJMoa2107934Gupta, Kaur, Yadav, Mukhopadhyay, Sahay et al., Clinical characterization and genomic analysis of samples from COVID-19 breakthrough infections during the second wave among the various states of India, Viruses,
doi:10.3390/v13091782Harder, Külper-Schiek, Reda, Treskova-Schwarzbach, Koch et al., Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25, Euro Surveill,
doi:10.2807/1560-7917.ES.2021.26.41.2100920Kim, Jang, Hong, Jung, Park et al., Safety, virologic efficacy, and pharmacokinetics of CT-P59, a neutralizing monoclonal antibody against SARS-CoV-2 spike receptor-binding protein: two randomized, placebo-controlled, phase I studies in healthy individuals and patients with mild SARS-CoV-2 infection, Clin Ther,
doi:10.1016/j.clinthera.2021.08.009Kim, Ryu, Lee, Kim, Seo et al., A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein, Nat Commun,
doi:10.1038/s41467-020-20602-5Kumar, Banu, Sasikala, Parsa, Sowpati et al., Effectiveness of REGEN-COV antibody cocktail against the B.1.617.2 (delta) variant of SARS-CoV-2: a cohort study, J Intern Med,
doi:10.1111/joim.13408Lee, Lee, Lee, Kim, Lee et al., Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: a propensity scorematched retrospective cohort study, Int Immunopharmacol,
doi:10.1016/j.intimp.2022.108570Liu, Huuskonen, Laitinen, Redchuk, Bogacheva et al., SARS-CoV-2-host proteome interactions for antiviral drug discovery, Mol Syst Biol,
doi:10.15252/msb.202110396Mahase, Delta variant: what is happening with transmission, hospital admissions, and restrictions, BMJ,
doi:10.1136/bmj.n1513O'horo, Challener, Speicher, Bosch, Seville et al., Effectiveness of monoclonal antibodies in preventing severe COVID-19 with emergence of the delta variant, Mayo Clin Proc,
doi:10.1016/j.mayocp.2021.12.002Park, Kim, Lee, Rhee, Kim et al., Update 2021 status and characteristics of COVID-19 variant virus outbreak in the Republic of Korea
Planas, Veyer, Baidaliuk, Staropoli, Guivel-Benhassine et al., Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization, Nature,
doi:10.1038/s41586-021-03777-9Ryu, Kang, Noh, Woo, Lee et al., The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2, Biochem Biophys Res Commun,
doi:10.1016/j.bbrc.2021.09.023Sheikh, Mcmenamin, Taylor, Cpublic, Health Scotland and the EAVE II Collaborators. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness, Lancet,
doi:10.1016/S0140-6736(21)01358-1Streinu-Cercel, Preotescu, Kim, Kim, Cheon, Efficacy and safety of regdanvimab (CT-P59): a phase 2/3 randomized, doubleblind, placebo-controlled trial in outpatients with mild-to-moderate coronavirus disease 2019, Open Forum Infect Dis,
doi:10.1093/ofid/ofac053Taylor, Patel, Pham, Whitaker, Anglin et al., Severity of disease among adults hospitalized with laboratory-confirmed COVID-19 before and during the period of SARS-CoV-2 B.1.617.2 (Delta) predominance -COVID-NET, 14 states, MMWR Morb Mortal Wkly Rep,
doi:10.15585/mmwr.mm7043e1Tian, Sun, Zhou, Ye, The global epidemic of the SARS-CoV-2 delta variant, key spike mutations and immune escape, Front Immunol,
doi:10.3389/fimmu.2021.751778Twohig, Nyberg, Zaidi, Thelwall, Sinnathamby et al., Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study, Lancet Infect Dis,
doi:10.1016/S1473-3099(21)00475-8Weinreich, Sivapalasingam, Norton, Ali, Gao et al., REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2035002Zhu, Zhang, Li, Yang, Song, A novel coronavirus from patients with pneumonia in China, 2019, N Engl J Med,
doi:10.1056/NEJMoa2001017
